Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction.
Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Vuilliomenet A, Muller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Khattab AA, Taniwaki M, Rigamonti F, Nietlispach F, Blöchlinger S, Wenaweser P, Jüni P, Windecker S. Pilgrim T, et al. Among authors: weilenmann d. EuroIntervention. 2016 Dec 10;12(11):e1343-e1354. doi: 10.4244/EIJY15M12_09. EuroIntervention. 2016. PMID: 26690319 Free article. Clinical Trial.
Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design.
Pfisterer M, Bertel O, Bonetti PO, Brunner-La Rocca HP, Eberli FR, Erne P, Galatius S, Hornig B, Kiowski W, Pachinger O, Pedrazzini G, Rickli H, De Servi S, Kaiser C; BASKET-PROVE Investigators. Pfisterer M, et al. Am Heart J. 2008 Apr;155(4):609-14. doi: 10.1016/j.ahj.2007.11.011. Epub 2008 Feb 21. Am Heart J. 2008. PMID: 18371466 Clinical Trial.
Drug-eluting versus bare-metal stents in large coronary arteries.
Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Bertel O, Bonetti P, De Servi S, Brunner-La Rocca HP, Ricard I, Pfisterer M; BASKET–PROVE Study Group. Kaiser C, et al. N Engl J Med. 2010 Dec 9;363(24):2310-9. doi: 10.1056/NEJMoa1009406. Epub 2010 Nov 16. N Engl J Med. 2010. PMID: 21080780 Free article. Clinical Trial.
Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial.
Pilgrim T, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Heg D, Jüni P, Windecker S. Pilgrim T, et al. Among authors: weilenmann d. Am Heart J. 2014 Sep;168(3):256-61. doi: 10.1016/j.ahj.2014.06.004. Epub 2014 Jun 6. Am Heart J. 2014. PMID: 25173535 Free article. Clinical Trial.
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
Pilgrim T, Heg D, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Fahrni T, Moschovitis A, Noble S, Eberli FR, Wenaweser P, Jüni P, Windecker S. Pilgrim T, et al. Among authors: weilenmann d. Lancet. 2014 Dec 13;384(9960):2111-22. doi: 10.1016/S0140-6736(14)61038-2. Epub 2014 Sep 1. Lancet. 2014. PMID: 25189359 Clinical Trial.
Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial.
Kaiser C, Galatius S, Jeger R, Gilgen N, Skov Jensen J, Naber C, Alber H, Wanitschek M, Eberli F, Kurz DJ, Pedrazzini G, Moccetti T, Rickli H, Weilenmann D, Vuillomenet A, Steiner M, Von Felten S, Vogt DR, Wadt Hansen K, Rickenbacher P, Conen D, Müller C, Buser P, Hoffmann A, Pfisterer M; BASKET-PROVE II study group. Kaiser C, et al. Among authors: weilenmann d. Circulation. 2015 Jan 6;131(1):74-81. doi: 10.1161/CIRCULATIONAHA.114.013520. Epub 2014 Nov 19. Circulation. 2015. PMID: 25411159 Clinical Trial.
Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial.
Franzone A, Pilgrim T, Heg D, Roffi M, Tüller D, Vuilliomenet A, Muller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Räber L, Stortecky S, Wenaweser P, Jüni P, Windecker S. Franzone A, et al. Among authors: weilenmann d. Circ Cardiovasc Interv. 2015 Jun;8(6):e002319. doi: 10.1161/CIRCINTERVENTIONS.114.002319. Circ Cardiovasc Interv. 2015. PMID: 26043895 Clinical Trial.
Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
Zbinden R, Piccolo R, Heg D, Roffi M, Kurz DJ, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Franzone A, Eberli F, Jüni P, Windecker S, Pilgrim T. Zbinden R, et al. Among authors: weilenmann d. J Am Heart Assoc. 2016 Mar 15;5(3):e003255. doi: 10.1161/JAHA.116.003255. J Am Heart Assoc. 2016. PMID: 26979080 Free PMC article. Clinical Trial.
Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction: Insights From the 2-Year Follow-Up of the BIOSCIENCE Trial.
Piccolo R, Heg D, Franzone A, Roffi M, Tüller D, Vuilliomenet A, Muller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Iglesias JF, Windecker S, Pilgrim T. Piccolo R, et al. Among authors: weilenmann d. JACC Cardiovasc Interv. 2016 May 9;9(9):981-3. doi: 10.1016/j.jcin.2016.02.044. JACC Cardiovasc Interv. 2016. PMID: 27151616 Free article. No abstract available.
93 results